Essex Bio-Technology Limited (HKG:1061)
Hong Kong · Delayed Price · Currency is HKD 3.620
-0.080 (-2.16%)
Apr 2, 2026, 4:08 PM HKT
Essex Bio-Technology Cash Flow Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 307.22 | 275.26 | 225.41 | 345.97 |
Depreciation & Amortization | 50.71 | 54.26 | 36.43 | 27.44 |
Other Amortization | 5.17 | 5.61 | 5.48 | 5.54 |
Loss (Gain) From Sale of Assets | 0.48 | 2.22 | 0.29 | 0.28 |
Asset Writedown & Restructuring Costs | 2.88 | 5.05 | 38.84 | - |
Loss (Gain) From Sale of Investments | -0.93 | -12.72 | 4.76 | 31.9 |
Loss (Gain) on Equity Investments | 2.91 | 1.64 | 0.19 | - |
Stock-Based Compensation | - | - | 0.09 | 0.26 |
Provision & Write-off of Bad Debts | 7.19 | - | - | - |
Other Operating Activities | -13.87 | 59.51 | -21.22 | 58.13 |
Change in Accounts Receivable | 12.94 | -131.75 | 200.64 | -169.17 |
Change in Inventory | -2.25 | 16.79 | 9.49 | 8.68 |
Change in Accounts Payable | 17.08 | 70.9 | -105.56 | 80.58 |
Change in Other Net Operating Assets | -21.06 | -7.58 | -12.06 | 19.56 |
Operating Cash Flow | 368.47 | 339.21 | 382.79 | 409.16 |
Operating Cash Flow Growth | 8.63% | -11.39% | -6.45% | 36.73% |
Capital Expenditures | -44.4 | -21.03 | -89.49 | -90.05 |
Sale of Property, Plant & Equipment | 0.75 | 0.11 | 0.06 | 0.13 |
Cash Acquisitions | - | - | 3.47 | 0.03 |
Sale (Purchase) of Intangibles | -75.07 | -107.01 | -193.42 | -164.85 |
Investment in Securities | 2.33 | 0.37 | -3.05 | -2.94 |
Other Investing Activities | 12.94 | 73.22 | -9.69 | -6.11 |
Investing Cash Flow | -106.59 | -54.34 | -302.03 | -280.08 |
Long-Term Debt Issued | 106.9 | 42.74 | - | 55.45 |
Total Debt Issued | 106.9 | 42.74 | - | 55.45 |
Long-Term Debt Repaid | -183.38 | -284.23 | -84.12 | -57.59 |
Total Debt Repaid | -183.38 | -284.23 | -84.12 | -57.59 |
Net Debt Issued (Repaid) | -76.48 | -241.49 | -84.12 | -2.14 |
Issuance of Common Stock | - | - | - | 1.89 |
Repurchase of Common Stock | -1.13 | -12.59 | -14.79 | -8.68 |
Common Dividends Paid | -59.58 | -39.92 | -54.53 | -51.89 |
Other Financing Activities | -63.62 | -15.92 | -15.67 | -12.31 |
Financing Cash Flow | -200.81 | -309.92 | -169.11 | -73.13 |
Foreign Exchange Rate Adjustments | -13.75 | -8.58 | -39.49 | 15.61 |
Net Cash Flow | 47.32 | -33.64 | -127.85 | 71.55 |
Free Cash Flow | 324.07 | 318.17 | 293.29 | 319.12 |
Free Cash Flow Growth | 1.85% | 8.48% | -8.09% | 57.87% |
Free Cash Flow Margin | 19.41% | 18.32% | 22.26% | 19.49% |
Free Cash Flow Per Share | 0.56 | 0.53 | 0.49 | 0.53 |
Cash Interest Paid | 63.62 | 15.92 | 15.67 | 12.31 |
Cash Income Tax Paid | 62.28 | 18.32 | 49.2 | -9.53 |
Levered Free Cash Flow | 224.76 | 204.67 | 65.84 | 6.38 |
Unlevered Free Cash Flow | 228.57 | 211.68 | 73.01 | 12.15 |
Change in Working Capital | 6.72 | -51.64 | 92.52 | -60.35 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.